Oncology Business Management

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

An interview with Frank G. Opelka, MD, exploring some of the health policy initiatives that will impact how physicians will be compensated in the future.

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Interview With Andrew Pecora, MD, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, Editor-in-Chief, Oncology & Biotech News

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.